Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases (Qatar)
18 Years
90 Years
Both
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Lung Cancer
Trial Information
Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases (Qatar)
This protocol is designed to collect a small amount of blood for extraction of DNA (genetic
material) for the study of the genetic basis of lung disease. The study population will
include individuals with known lung diseases and controls without lung disease. Individuals
in the study population will be individuals at the Hamad Medical Corporation, Qatar (HMC),
as well as other individuals recruited for this study. In this protocol, researchers will
survey medical records of patients with chronic lung disease, in order to study the clinical
characteristics of these individuals, and the researchers will collect blood to evaluate the
genetic characteristics of individuals with chronic lung diseases including asthma, and COPD
(chronic obstructive pulmonary disease), pulmonary fibrosis, and lung cancer. The
researchers will also collect blood samples of individuals without lung disease to serve as
control.
This protocol, to be carried out at Weill Cornell Medical College - Qatar and Hamad Medical
Corporation, Qatar, parallels a similar approved protocol IRB #0508008095, entitled,
"Collection of Blood for Gene Expression/Genomic Studies in Individuals with Chronic Lung
Diseases", ongoing at Weill Cornell Medical College - New York.
Lung Disease group. Individuals with lung disease who fit the following criteria will be
enrolled.
Inclusion criteria
- Must provide informed consent
- Males and females, age 18 years and older
- Evidence of lung disease proven by at least one of the following: (1) symptoms
consistent with pulmonary disease; (2) chest X-rays and/or chest CT consistent with
lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung
biopsy consistent with lung disease; (5) family history of lung disease; and (6)
diseases of organs with known association with lung disease; and (7) individuals
suspected of history of lung diseased based on history and/or physical examination
Exclusion criteria
- Individual refuses consent.
Normal control group. For the purpose of this protocol, "normal" will include individuals
without history of chronic lung disease, including asthma, and without recurrent or recent
(within 3 months) acute pulmonary disease, and will be determined by the following
criteria:
Inclusion Criteria:
- Must provide informed consent.
- Males or females ages 18 years and older.
- Non-smokers, ex-smokers and smokers.
Exclusion Criteria:
- Individual refuses consent.
- Individuals with history of chronic lung disease, including asthma or with
recurrent or recent (within three months) acute pulmonary disease will not be
accepted into the study.
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Principal Investigator
Ronald G Crystal, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Weill Cornell Medical College, NY and Qatar
Authority:
United States: Institutional Review Board
Study ID:
0605008516
NCT ID:
NCT00504361
Start Date:
May 2006
Completion Date:
May 2012
Related Keywords:
- Asthma
- COPD
- Interstitial Lung Disease
- Cystic Fibrosis
- Lung Cancer
- Asthma
- COPD
- Interstitial Lung Disease
- Cystic Fibrosis
- Lung Cancer
- smokers
- non-smokers
- Asthma
- Cystic Fibrosis
- Fibrosis
- Lung Diseases
- Pulmonary Disease, Chronic Obstructive
- Lung Neoplasms
- Pulmonary Fibrosis
- Lung Diseases, Interstitial
Name | Location |
|---|
